• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

姜黄素制剂的口服生物利用度比较优势。

Comparative oral bioavailability advantage from curcumin formulations.

机构信息

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector-67, S.A.S. Nagar, Punjab, 160062, India.

出版信息

Drug Deliv Transl Res. 2011 Aug;1(4):322-31. doi: 10.1007/s13346-011-0033-3.

DOI:10.1007/s13346-011-0033-3
PMID:25788366
Abstract

The aim of the present study was to study the oral bioavailability of seven different formulations of curcumin (CRM). CRM formulations viz. aqueous suspension, micronized suspension, nanosuspension, amorphous solid dispersion, hydroxypropyl-β-cyclodextrin (HP-β-CD) inclusion complex, combination with piperine, and spray-dried CRM-milk composite were compared for oral bioavailability in male Sprague-Dawley rats at a CRM dose of 250 mg/kg body weight using a validated high-performance liquid chromatography method. Aqueous suspension provided a C max and AUC(0 - t) of 28.9 ng/ml and 26.9 ng h/ml, respectively. In comparison, statistically significant increase in the oral bioavailability was obtained with the nanosuspension, HP-β-CD inclusion complex, and amorphous solid dispersion with 251%, 567%, and 446% increase in terms of AUC(0 - t) and 405%, 415%, and 270% in terms of C max. However, no significant increase in AUC(0 - t) and C max was observed with piperine and micronized suspension. The milk composite reduced the oral bioavailability of CRM (10% and 37% in terms of AUC(0 - t) and C max). A statistically significant increase in the T max was observed with piperine and in HP-β-CD complex, while the T max was reduced for nanosuspension. The results provide interesting insights into the role of solubility enhancement and metabolism inhibition, for improving the oral bioavailability of CRM.

摘要

本研究旨在研究七种不同姜黄素(CRM)制剂的口服生物利用度。在雄性 Sprague-Dawley 大鼠中,以 250mg/kg 体重的 CRM 剂量,用经验证的高效液相色谱法比较了 CRM 制剂,即水性混悬液、微米化混悬液、纳米混悬液、无定形固体分散体、羟丙基-β-环糊精(HP-β-CD)包合物、与胡椒碱联合使用以及喷雾干燥的 CRM-牛奶复合物的口服生物利用度。水性混悬液提供了 28.9ng/ml 的 C max 和 26.9ng·h/ml 的 AUC(0-t)。相比之下,纳米混悬液、HP-β-CD 包合物和无定形固体分散体的口服生物利用度显著增加,AUC(0-t)分别增加了 251%、567%和 446%,C max 分别增加了 405%、415%和 270%。然而,胡椒碱和微米化混悬液并没有显著增加 AUC(0-t)和 C max。牛奶复合物降低了 CRM 的口服生物利用度(AUC(0-t)和 C max 分别降低了 10%和 37%)。胡椒碱和 HP-β-CD 复合物使 T max 统计学上显著增加,而纳米混悬液使 T max 降低。结果为提高 CRM 的口服生物利用度提供了关于溶解度增强和代谢抑制作用的有趣见解。

相似文献

1
Comparative oral bioavailability advantage from curcumin formulations.姜黄素制剂的口服生物利用度比较优势。
Drug Deliv Transl Res. 2011 Aug;1(4):322-31. doi: 10.1007/s13346-011-0033-3.
2
Phase behavior and oral bioavailability of amorphous Curcumin.无定形姜黄素的相态行为和口服生物利用度。
Eur J Pharm Sci. 2012 Aug 30;47(1):56-64. doi: 10.1016/j.ejps.2012.05.003. Epub 2012 May 15.
3
Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.羟丙基-β-环糊精-氟他胺包合物。II. 氟他胺在大鼠体内的口服及静脉药代动力学
J Pharm Pharm Sci. 2002 Sep-Dec;5(3):292-8.
4
Preparation, characterization, and pharmacokinetics study of capsaicin via hydroxypropyl-beta-cyclodextrin encapsulation.辣椒素经羟丙基-β-环糊精包封的制备、表征及药代动力学研究
Pharm Biol. 2016;54(1):130-8. doi: 10.3109/13880209.2015.1021816. Epub 2015 Apr 8.
5
Novel lipid based oral formulation of curcumin: development and optimization by design of experiments approach.新型基于脂质的姜黄素口服制剂:通过实验设计方法的开发和优化。
Int J Pharm. 2012 Oct 15;436(1-2):617-23. doi: 10.1016/j.ijpharm.2012.07.031. Epub 2012 Jul 27.
6
A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.一项单剂量、三周期、六序列交叉研究,比较了空腹条件下健康墨西哥志愿者中镁丙戊酸盐溶液、混悬液和肠溶片剂的生物利用度。
Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016.
7
Ocular pharmacokinetics profile of different indomethacin topical formulations.不同吲哚美辛局部制剂的眼部药代动力学特征。
J Ocul Pharmacol Ther. 2011 Dec;27(6):571-6. doi: 10.1089/jop.2011.0120. Epub 2011 Nov 7.
8
Preparation and enhancement of oral bioavailability of curcumin using microemulsions vehicle.采用微乳液载体制备和增强姜黄素的口服生物利用度。
J Agric Food Chem. 2012 Jul 25;60(29):7137-41. doi: 10.1021/jf204078t. Epub 2012 Jul 10.
9
Pharmacokinetics of orally disintegrating tablets of perphenazine/hydroxypropyl-beta-cyclodextrin inclusion complex in rabbits.奋乃静/羟丙基-β-环糊精包合物口腔崩解片在兔体内的药代动力学
Pharmazie. 2013 Oct;68(10):800-4.
10
Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.400毫克阿昔洛韦的两种口服混悬剂和两种口服片剂剂型的生物利用度:在健康墨西哥成年受试者中进行的两项单剂量、开放标签、随机、两期交叉比较。
Clin Ther. 2007 Jun;29(6):1146-52. doi: 10.1016/j.clinthera.2007.06.007.

引用本文的文献

1
Development of a new micellar formulation of carvedilol and curcumin to enhance blood pressure reduction in a spontaneously hypertensive rat model.开发一种新的卡维地洛和姜黄素胶束制剂,以增强自发性高血压大鼠模型的血压降低效果。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):4165-4177. doi: 10.1007/s00210-024-03537-2. Epub 2024 Oct 18.
2
The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management.姜黄素的光明面:关于其在癌症治疗中潜在治疗作用的叙述性综述
Cancers (Basel). 2024 Jul 18;16(14):2580. doi: 10.3390/cancers16142580.
3
Antitumoral Activities of Curcumin and Recent Advances to ImProve Its Oral Bioavailability.

本文引用的文献

1
Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions.通过 O/W 纳米乳增强姜黄素的抗炎活性。
Food Chem. 2008 May 15;108(2):419-24. doi: 10.1016/j.foodchem.2007.10.086. Epub 2007 Nov 17.
2
Bioavailability enhancement of curcumin by complexation with phosphatidyl choline.姜黄素与磷脂酰胆碱复合提高生物利用度。
J Pharm Sci. 2011 May;100(5):1987-95. doi: 10.1002/jps.22393. Epub 2010 Nov 24.
3
Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin.
姜黄素的抗肿瘤活性及提高其口服生物利用度的最新进展
Biomedicines. 2021 Oct 14;9(10):1476. doi: 10.3390/biomedicines9101476.
4
Antineuroinflammatory Activities and Neurotoxicological Assessment of Curcumin Loaded Solid Lipid Nanoparticles on LPS-Stimulated BV-2 Microglia Cell Models.姜黄素载固体脂质纳米粒的抗神经炎症活性及神经毒性评价对 LPS 刺激的 BV-2 小胶质细胞模型。
Molecules. 2019 Mar 25;24(6):1170. doi: 10.3390/molecules24061170.
5
Bringing Curcumin to the Clinic in Cancer Prevention: a Review of Strategies to Enhance Bioavailability and Efficacy.将姜黄素应用于癌症预防临床:提高生物利用度和疗效的策略综述
AAPS J. 2017 Jan;19(1):54-81. doi: 10.1208/s12248-016-0003-2. Epub 2016 Oct 25.
6
Bioavailability of a lipidic formulation of curcumin in healthy human volunteers.姜黄素脂类剂型在健康人体志愿者中的生物利用度。
Pharmaceutics. 2012 Oct 9;4(4):517-30. doi: 10.3390/pharmaceutics4040517.
7
Curcumin nanomedicine: a road to cancer therapeutics.姜黄素纳米医学:癌症治疗的新途径。
Curr Pharm Des. 2013;19(11):1994-2010. doi: 10.2174/138161213805289219.
用于姜黄素持续全身递送的聚合物植入物的开发和体内外评价。
Pharm Res. 2011 May;28(5):1121-30. doi: 10.1007/s11095-011-0375-z. Epub 2011 Feb 11.
4
Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model.采用 Caco-2 细胞模型鉴定姜黄素口服传递中的通透性相关障碍。
Eur J Pharm Biopharm. 2011 Feb;77(2):275-82. doi: 10.1016/j.ejpb.2010.12.006. Epub 2010 Dec 13.
5
Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin.探索固体脂质纳米粒以提高姜黄素的口服生物利用度。
Mol Nutr Food Res. 2011 Mar;55(3):495-503. doi: 10.1002/mnfr.201000310. Epub 2010 Oct 11.
6
Solubility increases associated with crystalline drug nanoparticles: methodologies and significance.药物结晶纳米粒子的溶解度增加:方法学及意义。
Mol Pharm. 2010 Oct 4;7(5):1858-70. doi: 10.1021/mp100209b. Epub 2010 Sep 16.
7
Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability.自微乳药物传递系统提高姜黄素的溶解度和生物利用度。
Drug Dev Ind Pharm. 2011 Jan;37(1):15-23. doi: 10.3109/03639045.2010.489560. Epub 2010 Aug 25.
8
Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats.姜黄素自微乳制剂和微丸制剂的研制与评价及其在大鼠体内的吸收研究。
Eur J Pharm Biopharm. 2010 Nov;76(3):475-85. doi: 10.1016/j.ejpb.2010.07.011. Epub 2010 Jul 24.
9
Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.姜黄素包载 PLGA 纳米粒的制备及其对转移性癌细胞治疗效果的改善。
J Colloid Interface Sci. 2010 Nov 1;351(1):19-29. doi: 10.1016/j.jcis.2010.05.022. Epub 2010 May 12.
10
Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake.环糊精包合姜黄素通过提高细胞摄取率,表现出优于姜黄素的抗炎和抗增殖活性。
Biochem Pharmacol. 2010 Oct 1;80(7):1021-32. doi: 10.1016/j.bcp.2010.06.022. Epub 2010 Jun 23.